Dr. Bernard Leman, MD
Claim this profileIowa Digestive Disease Center
Studies Ulcerative Colitis
Studies Inflammatory Bowel Disease
3 reported clinical trials
2 drugs studied
Affiliated Hospitals
Clinical Trials Bernard Leman, MD is currently running
ABX464
for Ulcerative Colitis
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
Recruiting1 award Phase 36 criteria
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106. All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg open label treatment arms (Part #2) depending on their clinical response at the end of induction. This study consists of a 44-week treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
Recruiting1 award Phase 3
More about Bernard Leman, MD
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Bernard Leman, MD has experience with
- ABX464
- CDPATH™
Breakdown of trials Bernard Leman, MD has run
Inflammatory Bowel Disease
Crohn's Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bernard Leman, MD specialize in?
Bernard Leman, MD focuses on Ulcerative Colitis and Inflammatory Bowel Disease. In particular, much of their work with Ulcerative Colitis has involved treating patients, or patients who are undergoing treatment.
Is Bernard Leman, MD currently recruiting for clinical trials?
Yes, Bernard Leman, MD is currently recruiting for 2 clinical trials in Clive Iowa. If you're interested in participating, you should apply.
Are there any treatments that Bernard Leman, MD has studied deeply?
Yes, Bernard Leman, MD has studied treatments such as ABX464, CDPATH™.
What is the best way to schedule an appointment with Bernard Leman, MD?
Apply for one of the trials that Bernard Leman, MD is conducting.
What is the office address of Bernard Leman, MD?
The office of Bernard Leman, MD is located at: Iowa Digestive Disease Center, Clive, Iowa 50325 United States. This is the address for their practice at the Iowa Digestive Disease Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.